261 related articles for article (PubMed ID: 10882333)
21. Expanding the criteria for BRCA mutation testing in breast cancer survivors.
Kwon JS; Gutierrez-Barrera AM; Young D; Sun CC; Daniels MS; Lu KH; Arun B
J Clin Oncol; 2010 Sep; 28(27):4214-20. PubMed ID: 20733129
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.
Manser R; Dalton A; Carter R; Byrnes G; Elwood M; Campbell DA
Lung Cancer; 2005 May; 48(2):171-85. PubMed ID: 15829317
[TBL] [Abstract][Full Text] [Related]
23. Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts.
Vogel VG
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4413s-4418s; discussion 4411s-4412s. PubMed ID: 11916233
[TBL] [Abstract][Full Text] [Related]
24. The cost of prostate cancer chemoprevention: a decision analysis model.
Svatek RS; Lee JJ; Roehrborn CG; Lippman SM; Lotan Y
Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1485-9. PubMed ID: 16896037
[TBL] [Abstract][Full Text] [Related]
25. Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer.
Zeliadt SB; Etzioni RD; Penson DF; Thompson IM; Ramsey SD
Am J Med; 2005 Aug; 118(8):850-7. PubMed ID: 16084177
[TBL] [Abstract][Full Text] [Related]
26. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
27. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.
Goss PE; Ingle JN; Pater JL; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Cameron DA; Palmer MJ; Tu D
J Clin Oncol; 2008 Apr; 26(12):1948-55. PubMed ID: 18332475
[TBL] [Abstract][Full Text] [Related]
28. Is adjuvant therapy for older patients with node (+) early breast cancer cost-effective?
Naeim A; Keeler EB
Breast Cancer Res Treat; 2005 Nov; 94(2):95-103. PubMed ID: 16261407
[TBL] [Abstract][Full Text] [Related]
29. Interest in breast cancer chemoprevention among older women.
Tjia J; Micco E; Armstrong K
Breast Cancer Res Treat; 2008 Apr; 108(3):435-53. PubMed ID: 17554628
[TBL] [Abstract][Full Text] [Related]
30. Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation.
Karnon J
Health Econ; 2003 Oct; 12(10):837-48. PubMed ID: 14508868
[TBL] [Abstract][Full Text] [Related]
31. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N
J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model.
Hillner BE; Smith TJ
N Engl J Med; 1991 Jan; 324(3):160-8. PubMed ID: 1898533
[TBL] [Abstract][Full Text] [Related]
33. A model of chemotherapy in node-negative breast cancer.
Hillner BE; Smith TJ
J Natl Cancer Inst Monogr; 1992; (11):143-9. PubMed ID: 1627420
[TBL] [Abstract][Full Text] [Related]
34. Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis.
Grann VR; Jacobson JS; Thomason D; Hershman D; Heitjan DF; Neugut AI
J Clin Oncol; 2002 May; 20(10):2520-9. PubMed ID: 12011131
[TBL] [Abstract][Full Text] [Related]
35. Breast cancer prevention: a summary of the chemoprevention trial with tamoxifen.
Gould K; Gates ML; Miaskowski C
Oncol Nurs Forum; 1994 Jun; 21(5):835-40. PubMed ID: 7937245
[TBL] [Abstract][Full Text] [Related]
36. National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention Trial.
Giles K; Flynn PJ; Dalton R; Zera R
Minn Med; 1993 Dec; 76(12):25-7. PubMed ID: 8127293
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer.
Retèl VP; Joore MA; Knauer M; Linn SC; Hauptmann M; Harten WH
Eur J Cancer; 2010 May; 46(8):1382-91. PubMed ID: 20359886
[TBL] [Abstract][Full Text] [Related]
38. Chemoprevention Indication Score: a user-friendly tool for prevention of breast cancer - pilot analysis.
Layeequr Rahman R; Crawford S
Breast; 2009 Oct; 18(5):289-93. PubMed ID: 19716702
[TBL] [Abstract][Full Text] [Related]
39. [Is breast cancer prevention by tamoxifen possible?].
Namer M; Serin D; Ferrero JM
Bull Cancer; 1995 Jul; 82 Suppl 3():155s-167s. PubMed ID: 7492828
[TBL] [Abstract][Full Text] [Related]
40. The effect of physician recommendation on enrollment in the Breast Cancer Chemoprevention Trial.
Kinney AY; Richards C; Vernon SW; Vogel VG
Prev Med; 1998; 27(5 Pt 1):713-9. PubMed ID: 9808803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
